Successful Multimodal Therapy with Intracerebral Liposomal Amphotericin B and Systemic High-Dose Isavuconazole in Proven Disseminated Aspergillosis

J Fungi (Basel). 2023 Mar 7;9(3):327. doi: 10.3390/jof9030327.

Abstract

We report the case of a 32-year-old man receiving chemotherapeutics for an acute B-lymphoblastic leukemia who developed proven cerebral and pulmonary aspergillosis with Aspergillus flavus. Because of progressive fungal disease with neurological deterioration despite adequate systemic antifungal therapy and surgical debridement, intracerebral administration of liposomal amphotericin B was initiated at 5 mg twice weekly. This led to improvement of the cerebral infection. Surgical debridement of a pleural Aspergillus empyema was necessary, and pleural trough level of isavuconazole was found to be subtherapeutic despite adequate blood trough levels, which led us to increase the dose of isavuconazole. We conclude that intralesional amphotericin B might be beneficial at 5 mg twice weekly in cerebral aspergillosis if systemic antifungals and surgical debridement fail. In Aspergillus empyema, measurement of pleural isavuconazole trough levels should be considered.

Keywords: Aspergillus empyema; Aspergillus flavus; amphotericin B; aspergillosis; cerebral aspergillosis; isavuconazole.

Publication types

  • Case Reports

Grants and funding

This research received no external funding. S.F. acknowledges PhD fellowship funding from Research Foundation Flanders (FWO, grant number 11M6922N).